7 / 8
Page 19
Notes:
allied
academies
Journal of Microbiology: Current Research | Volume 2
November 01-02, 2018 | London, UK
7
th
European
Clinical Microbiology Congress
4
th
International Conference on
Ophthalmology and Eye Disorder
Joint Event
&
Management of
Helicobacter pylori
gastric infection via surface-grafted antimicrobial peptides
Paula Parreira
1,2
, Claudia Monteiro
1,2
, Vanessa Graça
2
, Joana Gomes
1,3
, Sílvia Maia
4
, Paula Gomes
4
, Inês C Gonçalves
1,2
and
M Cristina L
Martins
1,2,5*
1
Instituto de Investigação e Inovação em Saúde (i3S), Portugal
2
Instituto de Engenharia Biomédica, Portugal
3
Instituto de Patologia e Imunologia Molecular, Portugal
4
Universidade do Porto, Portugal
5
Instituto de Ciências Biomédicas Abel Salazar, Portugal
H
elicobacter pylori
chronic infection is associated, among
other severe gastric disorders, with intestinal-type gastric
carcinogenesis, being the fifth most common cancer and the
third leading cause of cancer-related death worldwide. Classical
H. pylori
eradication treatment, combining two antibiotics and
a proton pump inhibitor, reduces the risk for gastric carcinoma
development, but treatment of
H. pylori
infection is challenged
by a dramatic fall in eradication rates all over the world.
Currently, this bacterium is listed among the 16 antibiotic-
resistant bacteria that pose greatest threat to human health
according to the World Health Organization. Antimicrobial
peptides (AMPs) present an alternative to conventional
antibiotic therapies, being their most striking feature the low
tendency to induce bacterial resistance, since AMPs selectively
damage the bacterial membranes through mechanisms that
bacteria find difficult to evade. In an
in vivo
scenario, “unbound
AMPs” can undergo proteolysis and peptide aggregation,
leading to efficiency decrease. AMP grafting onto nanoparticles
has been reported as a good strategy to protect peptides from
aggregation and enzymatic degradation
in vivo
, therefore
increasing long-term stability and avoiding cytotoxicity
associated with application of high AMP concentrations. In
this study we demonstrated that the AMP MSI-78A could be
surface-grafted without compromising its activity. Moreover,
MSI-78A-decorated surfaces were highly effective against
H.
pylori
, killing bacteria by contact in a short time span, since
after 2h only 2% of
H. pylori
remained viable in suspension.
These results encourage the utilization of grafted MSI-78A on
biocompatible nanoparticles as an alternative to the currently
available therapy against
H. pylori
, opening new routes for
gastric infection management.
Speaker Biography
Paula Parreira graduated in Microbiology from the Universidade Católica Portuguesa
(Portugal) in 2007. In the same year, joined the team of Prof. M Cristina Martins at the
Institute of Biomedical Engineering of University of Porto (INEB) and from 2007 to 2013,
conducted her PhD studies under the guidance of Prof. M Cristina Martins and Prof.
Deborah Leckband (University of Illinois, at Urbana-Champaign, USA). After finishing
her PhD, Paula Parreira’s post doctoral research has continued to focus on development
of non-antibiotic strategies against microbiological human pathogens, namely against
the gastric pathogen
Helicobacter pylori
, with emphasis on natural molecules coupled
with bioengineered approaches. Currently, Paula Parreira is a research assistant in the
Bioengineered Surfaces Group at Instituto de Investigação e Inovação em Saúde (i3S;
Portugal) and has published several papers in first quartile journals, book chapters and
participated in several international conferences.
e:
parreira@i3s.up.ptPaula Parreira et al., Clinical Microbiology and Eye 2018, Volume 2
DOI: 10.4066/2591-8036-C1-002